Mohammed Solayman Hossain

Dr. Mohammed Solayman Hossain

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2024 in Medical Microbiology and Immunology
Verified
Journal Article
Open access
PDF file
ARAbdur Rahim
Abdur Rahim
HSHoonhee Seo
Hoonhee Seo
SKSukyung Kim
Sukyung Kim
IBIndrajeet Barman
Indrajeet Barman
FGFatemeh Ghorbanian
Fatemeh Ghorbanian
HSHo-Yeon Song
Ho-Yeon Song
Mycobacterium tuberculosis, a lethal pathogen in human history, causes millions of deaths annually, which demands the development of new concepts of drugs. Considering this fact, earlier research has explored the anti-tuberculosis potential of a probiotic strain, Lactocaseibacillus rhamnosus PMC203, leading to a subsequent focus on the molecular mechanism involved in its effect, particularly on autophagy. In this current study, immunoblotting-based assay exhibited a remarkable expression of autophagy marker LC3-II in the PMC203 treated group compared to an untreated group. A remarkable degradation of p62 was also noticed within treated cells compared to control. Furthermore, the immunofluorescence-based assay showed significant fold change in fluorescence intensity for alexa-647-LC3 and alexa-488-LC3, whereas p62 was degraded noticeably. Moreover, lysosomal biogenesis generation was elevated significantly in terms of LAMP1 and acidic vesicular organelles. As a result, PMC203-induced autophagy played a vital role in reducing M. tuberculosis burden within the macrophages in treated groups compared to untreated group. A colony -forming unit assay also revealed a significant reduction in M. tuberculosis in the treated cells over time. Additionally, the candidate strain significantly upregulated the expression of autophagy induction and lysosomal biogenesis genes. Together, these results could enrich our current knowledge of probiotics-mediated autophagy in tuberculosis and suggest its implications for innovatively managing tuberculosis.

9 January 2025 in Current Microbiology
Verified
Journal Article
Open access
PDF file
IBIndrajeet Barman
Indrajeet Barman
HSHoonhee Seo
Hoonhee Seo
SKSukyung Kim
Sukyung Kim
ARAbdur Rahim
Abdur Rahim
YYYoujin Yoon
Youjin Yoon
HSHo-Yeon Song
Ho-Yeon Song
Lactic acid bacteria (LAB), traditionally consumed as fermented foods, are now being applied to the medical field beyond health-functional food as probiotics. Therefore, it is necessary to continuously discover and evaluate new strains with suitable probiotic characteristics, mainly focusing on safety. In this study, we isolated eight new strains from postmenopausal vaginal fluid using culturomics approaches, an emerging area of interest. Data showed that most strains possessed significant cell surface hydrophobicity (≥ 76%), auto-aggregation capacity (17 to 61%), strong adhesion activity (8 to 34%), and excellent resistance to gastric acid, bile salt, and digestive enzyme, enhancing their survival in the gastrointestinal tract. Moreover, the strains exhibited functional characteristics, including substantial antibacterial activity with a minimal inhibitory concentration (MIC) ranging from 12.5 to 50%. They also harbored bacteriocins genes, produced short-chain fatty acids (acetate and propionate), exhibited significant phagocytic activity, possessed high antioxidative properties, rapidly depleted sodium nitrite, and exhibited proteolysis and β-glucosidase activity. In addition, heat-killed LAB strains significantly reduced the gene expressions of proinflammatory cytokines such as IL-β, IL-6, and iNOS in macrophages. Safety assessment revealed no cytotoxicity in macrophage cell lines. All strains tested negative for biogenic amine or H2O2 production, displayed no gelatinase or hemolytic activity, lacked virulence genes or detrimental enzymes, and displayed antibiotic susceptibility. In summary, these newly isolated strains demonstrate excellent probiotic functionality with a strong focus on safety, making them promising candidates for future drug development in the relevant fields.

12 December 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Md Sarower Hossen ShuvoMd Sarower Hossen Shuvo
Md Sarower Hossen Shuvo
SKSukyung Kim
Sukyung Kim
SJSujin Jo
Sujin Jo
Md Abdur RahimMd Abdur Rahim
Md Abdur Rahim
Indrajeet BarmanIndrajeet Barman
Indrajeet Barman
HSHo-Yeon Song
Ho-Yeon Song
Background/Objectives: Traditionally consumed fermented foods and lactic acid bacteria (LAB)-based products have primarily been investigated for their nutritional and health-promoting benefits as dietary supplements. More recently, research has advanced toward exploring their therapeutic potential in pharmaceutical development. However, reliance on conventional LAB strains despite their established safety and efficacy has led to saturation at the strain level, underscoring the need for next-generation probiotics (NGPs) with novel therapeutic potential. In this context, we identified Flavonifractor plautii from human feces as a candidate NGP and investigated its effects on the human gut microbiota. Methods: Whole-genome sequencing revealed distinct genetic features that supported its uniqueness, and the strain was designated PMC93. A human gut microbial ecosystem simulator was used to administer F. plautii daily for one week, after which microbial community changes were evaluated using 16S rRNA gene-based metagenomic sequencing. Results: The administration did not induce significant changes in alpha or beta diversity, suggesting that F. plautii does not disrupt overall bacterial community structure, thereby supporting its microbial community safety. Taxonomic analysis demonstrated a significant increase in the Firmicutes-to-Proteobacteria ratio (NGP F/P index). The improvement surpassed that of conventional LAB treatments and was consistently maintained under supplementation with commonly encountered pharmaceutical compounds and nutrients. The shift was associated with an increase in short-chain fatty acid (SCFA)-producing beneficial taxa and a decrease in pro-inflammatory and potentially pathogenic groups. Functional outcomes, including elevated SCFA levels and downregulation of inflammation-related gene expression, further corroborated these compositional changes. The strain also demonstrated safety in in vivo models. Conclusions: Collectively, these findings suggest that strain PMC93 is a promising NGP candidate with substantial therapeutic potential for microbiota-associated health and disease modulation, particularly due to its ability to enhance the NGP F/P index.

11 July 2024 in International Journal of Antimicrobial Agents
Verified
Journal Article
Open access
HSHoonhee Seo
Hoonhee Seo
YYYoujin Yoon
Youjin Yoon
SKSukyung Kim
Sukyung Kim
FGFatemeh Ghorbanian
Fatemeh Ghorbanian
HTHanieh Tajdozian
Hanieh Tajdozian
HSHo-Yeon Song
Ho-Yeon Song
Background: Tuberculosis is a highly contagious disease caused by Mycobacterium tuberculosis, and the increase in antibiotic resistance threatens humankind. Therefore, there is an urgent need to develop new anti-tuberculosis drugs that can overcome the limitations of existing drugs. Here, we report the anti-tuberculosis effect of microbiome therapeutic PMC205, a strain of Bacillus subtilis. Methods: The anti-tuberculosis activity of probiotics was evaluated in mouse models of lethal and latent pulmonary tuberculosis induced by high or low-dose infection of the extensively drug-resistant strain. Probiotics were administered by inhalation, and the burden of M. tuberculosis in the lungs, along with mortality and clinical observations, were monitored for 12 weeks and 8 months, respectively. For an in-depth understanding, analysis of the microbiome and inflammatory profile of the lung microenvironment and induction of autophagy in vitro were explored. Results: After inhalation administration of PMC205 for 3 months, the survival rate was 100%, unlike all deaths in the saline-treated group, and the burden of M. tuberculosis in the lungs was reduced by log 1.3 in the 8-month latent tuberculosis model. Moreover, PMC205 induced recovery of disrupted lung microflora, increased butyric acid, and suppressed excessive inflammation. It also promoted autophagy. Conclusions: These results confirm PMC205’s anti-tuberculosis effect, suggesting that it can be developed as an adjuvant to current antibiotic therapy to solve the drug-resistant tuberculosis problem.

31 May 2025 in Journal of Microbiology
Verified
Journal Article
Open access
Mohammed Solayman HossainMohammed Solayman Hossain
Mohammed Solayman Hossain
HSHoonhee Seo
Hoonhee Seo
KLKyung-Ann Lee
Kyung-Ann Lee
AUAsad Ul-Haq
Asad Ul-Haq
SKSukyung Kim
Sukyung Kim
HSHo-Yeon Song
Ho-Yeon Song
Gout is an inflammatory arthritis resulting from the deposition of monosodium urate crystals. Urate-lowering therapies for gout have limitations, including side effects and limited efficacy, highlighting the need for novel therapeutic approaches to improve patient outcomes. In this context, our research team conducted a microbiome analysis of fecal samples from healthy individuals and gout patients, identifying Bifidobacterium as a key biomarker. Subsequently, we isolated and identified this strain, B. longum PMC72, and demonstrated its efficacy in a gout mouse model. In potassium oxonate (PO)-induced hyperuricemia mice, PMC72 significantly alleviated nausea, gait disturbances, ankle inflammation, and improved renal health. These effects were associated with marked reductions in oxidative stress markers, including serum uric acid, blood urea nitrogen, hepatic xanthine oxidase, and malondialdehyde (MDA) levels in serum, liver, and joint samples, as well as the downregulation of inflammation and uric acid transport-related gene expression in kidney samples. These benefits were comparable to those treated with Febuxostat, a standard urate-lowering therapy for gout. Furthermore, gut microbiome analysis revealed that PMC72 restored dysbiosis induced by hyperuricemia, contrasting with the reduced microbial diversity observed with febuxostat alone, and showed a complete recovery to eubiosis when combined with Febuxostat. These findings position PMC72 as a promising microbial therapeutic candidate for gout management, demonstrating significant development potential and serving as a benchmark for reverse translational microbiome-based therapeutic research.

31 December 2024 in Journal of Bacteriology and Virology
Verified
Journal Article
Open access
PDF file
Mohammed Solayman HossainMohammed Solayman Hossain
Mohammed Solayman Hossain
HSHoonhee Seo
Hoonhee Seo
ARAbdur Rahim
Abdur Rahim
Md Sarower Hossen ShuvoMd Sarower Hossen Shuvo
Md Sarower Hossen Shuvo
IBIndrajeet Barman
Indrajeet Barman
HSHo-Yeon Song
Ho-Yeon Song
Tuberculosis (TB) remains a global health crisis, with the emergence of multidrugresistant strains necessitating the development of novel therapeutic strategies. Approximately one-fourth of the world's population, or 2 billion people, are infected with latent TB. The rise of multidrug-resistant (MDR), extensively drug-resistant (XDR), and totally drug-resistant (TDR) strains of Mycobacterium tuberculosis (M. tb) poses a significant threat, reducing the effectiveness of conventional treatments. The limitations of current antibiotic regimens underscore the urgent need for alternative approaches. This highlights the urgent need for new anti-tuberculosis drugs. Probiotics, known for their health benefits against various infections, may offer a promising alternative in combating antibiotic-resistant TB. This study aimed to identify novel probiotic strains with anti-tuberculosis potential. Seven probiotic strains were selected by screening with the GFP-TB in vitro model. Treatment with probiotic extracts significantly reduced the TB burden inside macrophage cells analyzed by confocal microscopy, ranging from 51% to 76%. The anti-tuberculosis efficacy of these candidate strains was further evaluated using CFU and resazurin assays, where treatment with probiotics resulted in up to a 1.25 log reduction of viable TB in the CFU assay. To ensure the probiotic strains were safe for therapeutic application, comprehensive safety assessments were conducted, including evaluations of cytotoxicity, antibiotic susceptibility test, hemolysis, bile salt deconjugation, and D-lactate assay. Following the safety confirmation, we investigated the underlying mechanisms by which these probiotic strains enhance immunity and facilitate the clearance of TB within macrophage cells in vitro. This involved assessing autophagy gene expression and nitrite reduction, which are established methods for studying anti-tuberculosis effects. The results of these mechanistic studies align with the CFU and confocal microscopy findings, indicating that at least three of the probiotic strains have the potential to mitigate tuberculosis infection significantly. This research provides a foundation for further exploration of these probiotic strains as potential biotherapeutics in tuberculosis treatment. However, further studies on toxicity, mechanism of action, and efficacy in animals, followed by clinical trials, are necessary.